Recombinant CD33 (Gemtuzumab Biosimilar) anticorps

N° du produit ABIN7795111

Cet anticorps anti-CD33 (Gemtuzumab Biosimilar) Monoclonal Humanized (ABIN7795111) détecte spécifiquement CD33 (Gemtuzumab Biosimilar) dans FACS et in vivo. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Recombinant CD33 (Gemtuzumab Biosimilar) anticorps (ABIN7795111)

Antigène: CD33 (Gemtuzumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp CD33 (Gemtuzumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-CD33 (Gemtuzumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Gemtuzumab Biosimilar, CD33 Monoclonal Antibody

Attributs du produit: Gemtuzumab is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50 % of the antibody loaded with 4-6 Moles calicheamicin per mole of antibody Label. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. Gemtuzumab is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Gemtuzumab with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double strand breaks via formation of a p-benzene diradical. Eventually, cell death is induced.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human CD33

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur CD33 (Gemtuzumab Biosimilar)

Antigène: CD33 (Gemtuzumab Biosimilar)

Autre désignation: Gemtuzumab Biosimilar

Classe de substances: Biosimilar